Regimens containing other anti-HER2 agents, such as TL (lapatinib + taxanes), TN (neratinib + taxanes), and T-DM1 and TdmP (T-DM1 + pertuzumab) were inferior to THP in all efficacy outcomes, suggesting that THP was still the optimal option to reach the best efficacy for metastatic HER2+ BC. Here, ERBB2 is linked to breast cancer.